HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review
- The product is injectable HS-20093 (Risvutatug Rezetecan), and the indication included in the priority review and approval procedure is for the treatment of osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy.
- The indication was included in the priority review and approval procedure based on positive results from the product's pivotal Phase III trial ARTEMIS-011.
NewTimeSpace News: On 22 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced on a voluntary basis that the indication of its injectable HS-20093 (Risvutatug Rezetecan) for the treatment of osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy was, on 14 September 2026, included in the priority review and approval procedure of China's National Medical Products Administration (NMPA). The announcement stated that the inclusion was based on positive results from the product's pivotal Phase III trial ARTEMIS-011. The announcement was made voluntarily by the Company.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANSOH PHARMA (03692.HK): Socrodeucitinib NDA accepted by NMPA for psoriasis
- HANSOH PHARMA (03692.HK): Almonertinib Wins Positive CHMP Opinion for EU Approval in NSCLC
- HANSOH PHARMA (03692.HK): AilsynBio Deal Gives Access to AI Platform for Oral Cyclic Peptides
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October